The Landscape of Diabetes Research Today
Diabetes affects roughly one in ten American adults, and the numbers keep climbing. Traditional management relies on lifestyle changes, oral medications, and insulin, but the past few years have brought a wave of innovation that goes beyond the pharmacy aisle.
One of the most talked-about developments in 2026 is the growing focus on endoscopic and device-based treatments for type 2 diabetes. Companies like Endogenex, based in Minnesota, recently completed enrollment of 350 patients across roughly 40 sites in the United States and Australia for the ReCET study, a randomized, sham-controlled trial examining whether a targeted endoscopic procedure can improve blood glucose control in adults whose type 2 diabetes isn't well managed with non-insulin medications. The primary endpoint measures change in HbA1c six months after the procedure, with all participants followed for a full year.
Similarly, Aqua Medical treated its first U.S. patient at UNC Health in Chapel Hill, North Carolina, in a study testing a through-the-scope ablation procedure designed to resurface a segment of the proximal small intestine. Early international data from 66 patients outside the U.S. showed encouraging safety results, with some treated patients reportedly eliminating insulin entirely.
On the pharmaceutical side, Roche's investigational drug Enicepatide, a once-weekly dual GLP-1/GIP receptor agonist, hit both primary endpoints in a Phase 2 trial for overweight or obese adults with type 2 diabetes, with results announced just this month. The company plans to launch Phase 3 blood sugar control and cardiovascular outcome studies in early 2027.
For type 1 diabetes, cell therapy continues to advance. Encellin reported interim Phase 1 results showing viable encapsulated human islets with non-fibrotic engraftment in initial study subjects, addressing a historical barrier in encapsulated cell replacement. And Vertex's VX-880 stem cell-derived islet therapy continues to generate headlines, with early participants achieving periods of insulin independence.
What ties these efforts together is a simple observation: standard treatment isn't enough for everyone, and researchers are increasingly looking beyond medication alone to address the underlying biology of the disease.
Understanding Trial Phases and What They Mean for You
Clinical trials in the U.S. follow a structured path. Phase 1 studies enroll small groups of 20 to 100 people to test safety and dosing. Phase 2 expands to a few hundred participants to evaluate effectiveness. Phase 3 involves large populations comparing the new treatment against standard care, and Phase 4 tracks long-term effects after approval.
For patients, the phase matters more than most people think. A Phase 3 trial like ReCET has substantial safety data behind it and a clear comparison against placebo or standard care. A Phase 1 trial like Encellin's offers access to genuinely novel science but carries more unknowns. Neither is inherently better — it depends on your health situation, your risk tolerance, and what you hope to gain.
| Trial Category | Example | Typical Duration | Best For | Main Benefits | Key Considerations |
|---|
| Drug Development | Roche Enicepatide (Phase 2/3) | 6 months to 2 years | People seeking next-generation medication options | Access to pre-approval therapies, close monitoring | Unknown long-term effects, potential side effects |
| Device/Procedure | Endogenex ReCET, Aqua Medical PIMA | 3 to 12 months | Those whose glucose control lags despite multiple medications | Minimally invasive options beyond pharmacotherapy | Procedure-related risks, travel to study sites |
| Cell Therapy | Vertex VX-880, Encellin ENCRT | 1 to 3 years | Type 1 patients with severe hypoglycemia unawareness | Potential for insulin independence | Early-stage uncertainty, intensive follow-up |
| Monitoring Technology | FreeDM2 (CGM for type 2) | 4 to 8 months | Adults on basal insulin wanting better daily data | Real-time glucose insight, fewer finger pricks | Device wear commitment, insurance coverage questions |
How to Find a Trial That Fits Your Life
Searching for diabetes clinical trials in the United States doesn't require a medical degree. The most reliable starting point is ClinicalTrials.gov, the NIH-maintained registry listing hundreds of thousands of studies. Enter your diabetes type in the condition field, filter by "Recruiting" status, and use the distance filter to find studies near you. Many trials now offer remote or hybrid participation, which widens the map considerably.
Beyond the national registry, several pathways are worth exploring:
- Academic medical centers like Mayo Clinic, Cleveland Clinic, Joslin Diabetes Center in Boston, and Stanford Diabetes Research Center frequently run their own trials and partner with national studies. Checking their clinical research pages directly can surface studies that haven't reached broader registries yet.
- Endocrinologists and primary care physicians often hear about local trials months before they appear in public listings. A straightforward conversation during your next visit can uncover options tailored to your specific health profile.
- Advocacy organizations including the American Diabetes Association and JDRF maintain trial-matching services and educational materials. JDRF is particularly active in type 1 research, while the ADA covers the full spectrum.
For example, someone in Texas searching for "type 2 diabetes clinical trials Houston" would find studies at Baylor College of Medicine, which has investigated new GLP-1 receptor agonists in recent years. A patient in Colorado might look to the Barbara Davis Center, which specializes in trials across all diabetes types.
What to Expect During the Screening Process
Joining a trial involves more than signing a form. The process typically unfolds in stages:
- Pre-screening: An online questionnaire or phone call to confirm you meet basic criteria like diabetes type, age range, and HbA1c levels.
- Informed consent: A detailed review of the study protocol, potential risks, benefits, and time commitments. This document is designed to be read carefully, not skimmed.
- Baseline visits: Blood work, physical exams, and sometimes additional tests to confirm eligibility and establish your starting point.
- Active participation: Following the trial protocol, which might mean taking an investigational medication, wearing a device, attending scheduled visits, or logging glucose readings.
- Follow-up: Most trials include a monitoring period after the intervention ends, sometimes extending a year or more.
Safety protections are rigorous. U.S. trials must comply with ethical standards overseen by the Office for Human Research Protections, and HIPAA regulations protect your personal health information. Critically, you can withdraw from a study at any time, for any reason, without penalty — a right that applies from the moment you enroll.
A case from California illustrates how this works in practice: a participant in a CGM trial developed skin irritation from the sensor, reported it to the research team, and chose to discontinue. The team addressed the issue and respected the withdrawal decision without pressure. That's how the system is supposed to function.
Practical Considerations Before You Enroll
Compensation varies widely by study. Some trials reimburse for time and travel, while others cover study-related medical care at no cost. Rather than focusing on payment, consider the bigger picture: what will participation require of your schedule, your body, and your current treatment routine?
Ask the research coordinator these questions before committing:
- Will my current medications need to change, and who manages those adjustments?
- Are study-related tests, devices, and procedures covered by the sponsor?
- What happens if I experience a side effect — who do I contact, and how quickly?
- If the trial ends, do I have continued access to the treatment while it awaits approval?
- How often are study visits, and are telehealth options available?
One patient's experience offers perspective. Sarah, a 54-year-old teacher in Ohio with type 2 diabetes, enrolled in a CGM-focused study after years of finger-prick monitoring left her frustrated with unpredictable readings. The trial gave her real-time glucose data she'd never had before, and she described the insight as life-changing, even though the device itself wasn't the intervention being tested. Her glucose control improved during the study period, and she continues to use a CGM today.
Regional Resources Worth Knowing
Certain parts of the country have become hubs for diabetes research. The Bay Area hosts Encellin and multiple cell therapy pioneers. Minneapolis is home to Endogenex and a growing medical device cluster. Boston's Joslin Diabetes Center remains a global reference point for type 1 research. North Carolina's Research Triangle combines academic centers like UNC and Duke with a dense biotech ecosystem.
But you don't need to live near a research hub to participate. Federally Qualified Health Centers across the country partner with researchers to include diverse populations, and many device trials ship equipment directly to participants. Telehealth follow-up has become standard since the pandemic, reducing the travel burden significantly.
The decision to join a diabetes management trial is deeply personal. For some, it's a chance to access treatments years before they reach the market. For others, it's a way to contribute to science that might help their children or grandchildren. And for a growing number of Americans, it's simply the most practical path to better glucose control when standard options have fallen short.
Before you take the next step, review your current treatment plan honestly with your care team. Ask whether a trial might complement or complicate what you're already doing. Then spend an evening on ClinicalTrials.gov with a cup of tea, filter for recruiting studies near you, and see what's out there. The research landscape in 2026 is richer than it has ever been, and the studies enrolling right now could shape diabetes care for the next decade.
研究の知恵